A Study to Analyse the Genetic Makeup of Those with Opioid and Substance Use Disorders

Overview

About this study

The purpose of this study is to establish an opioid and multiple addiction (OMA) biobank that creates a comprehensive standard patient phenotype using standardized subjective assessments and objective behavioral measurements for future research. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 13-90 years, male, female, any race/ethnicity.
  • At least one-time opioid lifetime exposure.
  • Categorized into OUD cases (based on clinical interview DSM-IV or DSM-V criteria) or an exposed control (no OUD diagnosis).

Exclusion Criteria:

  • Inability to speak English.
  • Inability or unwilling to provide consent.
  • Unwilling to consent to providing bio-specimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design.
  • Actively psychotic or suicidal.
  • Cognitive concerns.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Albert Lea, Minn.

Mayo Clinic principal investigator

Tyler Oesterle, M.D., M.P.H.

Contact us for the latest status

Contact information:

Sarah Williams

(507) 422-2972

Williams.Sarah2@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Tyler Oesterle, M.D., M.P.H.

Open for enrollment

Contact information:

Sarah Williams

(507) 422-2972

Williams.Sarah2@mayo.edu

More information

Publications

Publications are currently not available